Plain-English translation of NCT07552168 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
The INSPIRE trial is testing next-generation stereotactic ablative radiotherapy (SABR), a highly focused form of radiation therapy, for treating prostate cancer. This treatment delivers radiation in just 5 doses over about 2 weeks, with special techniques designed to protect nearby organs and reduce side effects like urinary and sexual problems. Researchers are comparing how well this newer approach works compared to what doctors have seen in previous studies.
Standard prostate radiation treatments often cause bothersome side effects affecting the bladder, bowel, and sexual function. This trial exists to see whether newer radiation planning techniques—including protecting the urethra, using spacers between the prostate and rectum, and preserving nerve bundles—can deliver effective cancer treatment while significantly reducing these unwanted side effects.
You likely qualify if…
You likely don't qualify if…
You will receive 5 doses of focused radiation therapy, given on alternate days over about 2 weeks. Before treatment, you'll have a small spacer gel injected between your prostate and rectum to protect your bowel. You'll have imaging scans and planning visits to map out your treatment precisely. After treatment ends, you'll have follow-up appointments at 2, 4, 8, and 12 weeks, then at 6 months, 9 months, and once a year for 5 years to check how you're doing, monitor any side effects, and complete questionnaires about your quality of life.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
Ireland
United Kingdom